Clinical Trials on Previously Treated Myelodysplastic Syndromes

Total 5676 results

City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

Acute Leukemia | Myelodysplastic Syndrome

United States
Peking University People's Hospital

Recruiting

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Myelodysplastic Syndromes | Acute Leukemia

China
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Completed

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

AML | MDS

United States
Sunnybrook Health Sciences Centre
Princess Margaret Hospital, Canada; Juravinski Cancer Center

Unknown

Red Blood Cell Transfusion Thresholds and QOL in MDS (EnhanceRBC)

Quality of Life | Myelodysplastic Syndromes (MDS) | Red Blood Cell (RBC) Transfusions

Canada
Memorial Sloan Kettering Cancer Center

Completed

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) | Acute Myelogenous Leukemia (AML)

United States
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Washington University School of Medicine
Cephalon

Completed

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Myelodysplastic Syndromes and Leukemia, Myeloid, Acute

United States
Li Junmin

Withdrawn

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Myelodysplastic Syndromes | P53 Mutation

China
Rennes University Hospital
Ministry of Health, France

Terminated

Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome (EPO)

Myelodysplastic Syndromes | Anemia | Hemopathies

France
University of Rochester

Not yet recruiting

A Telehealth Advance Care Planning Intervention (TeleSICP)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myelodysplastic/Myeloproliferative Neoplasm

United States
Celyad Oncology SA

Withdrawn

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (EPITHINK)

Myelodysplastic Syndromes | AML, Adult
European Working Group of MDS in Childhood

Unknown

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome

Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Germany
Washington University School of Medicine
American Society of Hematology

Recruiting

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

Myelodysplastic Syndromes | Whole Genome Sequencing

United States
Celgene

Completed

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Myelodysplastic Syndrome

Korea, Republic of
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
Massachusetts General Hospital
Novartis

Recruiting

MBG453 in Lower Risk MDS

Myelodysplastic Syndromes

United States
Technische Universität Dresden

Recruiting

Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

Myelodysplastic Syndromes

Germany
Xiao Li

Unknown

Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

Myelodysplastic Syndromes

China
iOMEDICO AG

Completed

Non-interventional Study With Azacitidin (Vidaza®) (Piaza)

AML | MDS | CMMOL

Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Technische Universität Dresden

Not yet recruiting

Lifestyle-modifying Interventions in Low-risk MDS Patients (MDS-LIME)

Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
University of California, San Francisco
Novartis

Completed

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Humanigen, Inc.

Suspended

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Myelodysplastic Syndrome (MDS) | Myelofibrosis (MF)

United States, Australia
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...

United States
Centre Hospitalier Universitaire, Amiens

Completed

Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes. (HEMASTEM)

Myelodysplastic Syndromes | Hematopoietic Cell Proliferation

France
Washington University School of Medicine

Completed

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Office of Rare Diseases (ORD)
Rare Diseases Clinical Research Network

Unknown

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
Schrödinger, Inc.

Recruiting

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic Syndromes

United States
University Hospital, Brest

Recruiting

Biocollection in MyeloDysplastic Syndrome (P-MDS) (P-MDS)

Myelodysplastic Syndromes | Chromosome Abnormality | Acute Myeloid Leukemia With Multilineage Dysplasia | Myelodysplastic Syndrome With Ring Sideroblasts | Myelodysplastic Anemia | Myelodysplastic Syndrome With Isolated Del(5Q)

France
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.; Forma Therapeutics, Inc.

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Teva Pharmaceuticals USA

Completed

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Leukemia

United States
Sunnybrook Health Sciences Centre
Health Sciences Centre, Winnipeg, Manitoba; The Ottawa Hospital; Jewish General... and other collaborators

Unknown

MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank (MDS)

Myelodysplastic Syndrome (MDS)

Canada
M.D. Anderson Cancer Center

Terminated

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13... and other conditions

United States

Clinical Trials on Previously Treated Myelodysplastic Syndromes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations